AN2 Therapeutics Management
Management criteria checks 3/4
AN2 Therapeutics' CEO is Eric Easom, appointed in Nov 2019, has a tenure of 5.5 years. total yearly compensation is $1.67M, comprised of 36.2% salary and 63.8% bonuses, including company stock and options. directly owns 4.28% of the company’s shares, worth $1.60M. The average tenure of the management team and the board of directors is 4.1 years and 5.3 years respectively.
Key information
Eric Easom
Chief executive officer
US$1.7m
Total compensation
| CEO salary percentage | 36.2% |
| CEO tenure | 5.5yrs |
| CEO ownership | 4.3% |
| Management average tenure | 4.1yrs |
| Board average tenure | 5.3yrs |
Recent management updates
Recent updates
We're Keeping An Eye On AN2 Therapeutics' (NASDAQ:ANTX) Cash Burn Rate
Nov 21
Is AN2 Therapeutics (NASDAQ:ANTX) In A Good Position To Invest In Growth?
Jul 04Here's Why We're Not Too Worried About AN2 Therapeutics' (NASDAQ:ANTX) Cash Burn Situation
Mar 23AN2 Therapeutics (NASDAQ:ANTX) Is In A Good Position To Deliver On Growth Plans
Dec 05AN2 Therapeutics (NASDAQ:ANTX) Is In A Good Position To Deliver On Growth Plans
Aug 20We Think AN2 Therapeutics (NASDAQ:ANTX) Can Afford To Drive Business Growth
May 09We're Not Very Worried About AN2 Therapeutics' (NASDAQ:ANTX) Cash Burn Rate
Feb 03We're Hopeful That AN2 Therapeutics (NASDAQ:ANTX) Will Use Its Cash Wisely
Oct 21AN2 Therapeutics secures $17.8M contract from NIH
Sep 29We Think AN2 Therapeutics (NASDAQ:ANTX) Can Afford To Drive Business Growth
Jul 01CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2024 | US$2m | US$604k | -US$51m |
| Sep 30 2024 | n/a | n/a | -US$61m |
| Jun 30 2024 | n/a | n/a | -US$65m |
| Mar 31 2024 | n/a | n/a | -US$66m |
| Dec 31 2023 | US$3m | US$575k | -US$65m |
| Sep 30 2023 | n/a | n/a | -US$60m |
| Jun 30 2023 | n/a | n/a | -US$54m |
| Mar 31 2023 | n/a | n/a | -US$49m |
| Dec 31 2022 | US$3m | US$481k | -US$43m |
| Sep 30 2022 | n/a | n/a | -US$40m |
| Jun 30 2022 | n/a | n/a | -US$38m |
| Mar 31 2022 | n/a | n/a | -US$35m |
| Dec 31 2021 | US$2m | US$377k | -US$28m |
Compensation vs Market: Eric's total compensation ($USD1.67M) is above average for companies of similar size in the US market ($USD682.63K).
Compensation vs Earnings: Eric's compensation has been consistent with company performance over the past year.
CEO
Eric Easom (55 yo)
5.5yrs
Tenure
US$1,666,117
Compensation
Mr. Eric E. Easom is Co-founder of AN2 Therapeutics, Inc. and has been its CEO, President & Director from November 19, 2019 and is its Chairman of the Board since June 2024. He served as Senior Director of...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 5.5yrs | US$1.67m | 4.28% $ 1.6m | |
| Co-Founder & Independent Chairman of the Board | 8yrs | US$169.93k | 1.83% $ 683.8k | |
| CFO, Principal Financial Officer & Principal Accounting Officer | 5.5yrs | US$812.70k | 0.050% $ 18.6k | |
| Chief Legal Officer | 2.7yrs | US$1.06m | 0.091% $ 33.9k | |
| Co-Founder & Senior Clinical Advisor | no data | no data | no data | |
| Co-Founder | no data | no data | no data | |
| Chief Development Officer | 5.5yrs | no data | 0.031% $ 11.4k | |
| Chief Strategy Officer | less than a year | no data | 0.033% $ 12.5k | |
| Senior VP of Research & Head of Chemistry | less than a year | no data | no data |
4.1yrs
Average Tenure
62yo
Average Age
Experienced Management: ANTX's management team is considered experienced (4.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 5.5yrs | US$1.67m | 4.28% $ 1.6m | |
| Co-Founder & Independent Chairman of the Board | 8yrs | US$169.93k | 1.83% $ 683.8k | |
| Independent Director | 3.3yrs | US$147.01k | 0% $ 0 | |
| Independent Director | 4.1yrs | US$159.17k | 0.021% $ 7.7k | |
| Lead Independent Director | 3yrs | US$159.08k | 0% $ 0 | |
| Independent Director | 5.5yrs | US$150.15k | 0.030% $ 11.3k | |
| Independent Director | 4.1yrs | US$158.51k | 0% $ 0 | |
| Independent Director | 5.5yrs | US$148.84k | 0.062% $ 23.2k | |
| Independent Director | 5.3yrs | US$149.87k | 0.14% $ 51.5k |
5.3yrs
Average Tenure
59yo
Average Age
Experienced Board: ANTX's board of directors are considered experienced (5.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/07 23:14 |
| End of Day Share Price | 2025/05/07 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
AN2 Therapeutics, Inc. is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Douglas Buchanan | Citizens JMP Securities, LLC |
| Liisa Bayko | Evercore ISI |
| Joseph Schwartz | Leerink Partners LLC |